ArticleScientific reports2020
Gut Microbiota Profiles of Treated Metabolic Syndrome Patients and their Relationship with Metabolic Health.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- Phage-microbe dynamics after sterile faecal filtrate transplantation in individuals with metabolic syndrome: a double-blind, randomised, placebo-controlled clinical trial assessing efficacy and safety.Nature communications · 2023Trial
- Comparison between Egg Intake versus Choline Supplementation on Gut Microbiota and Plasma Carotenoids in Subjects with Metabolic Syndrome.Nutrients · 2022Trial
- Overall Structural Alteration of Gut Microbiota and Relationships with Risk Factors in Patients with Metabolic Syndrome Treated with Inulin Alone and with Other Agents: An Open-Label Pilot Study.Mediators of inflammation · 2022Trial
- Gut microbiota composition and functional pathways associated with metabolic syndrome in Mexican adult women: cross-sectional analysis.BMC microbiology · 2026Article
- Gut Microbiome Dysbiosis in Metabolic Syndrome: Current Evidence and Emerging Perspectives.Nutrients · 2026Review
- Article
- Article
- Article
- Probiotics and functional foods in metabolic disease: emerging solutions for obesity and diabetes.Journal of diabetes and metabolic disorders · 2025Review
- Article
- Association between gut microbiome profiles and host metabolic health across the life course: a population-based study.The Lancet regional health. Europe · 2025Article
- Changes in the gut microbiome of older adults according to hypertension control.Frontiers in microbiology · 2025Article
- The interplay of factors in metabolic syndrome: understanding its roots and complexity.Molecular medicine (Cambridge, Mass.) · 2024Review
- A combination of rebaudioside A and neohesperidin dihydrochalcone suppressed weight gain by regulating visceral fat and hepatic lipid metabolism inFood science and biotechnology · 2024Article
- A Three-Dimensional Xeno-Free Culture Condition for Wharton's Jelly-Mesenchymal Stem Cells: The Pros and Cons.International journal of molecular sciences · 2023Article
- Characterization of the Gut Microbiota in Urban Thai Individuals Reveals Enterotype-Specific Signature.Microorganisms · 2023Article
- Gut microbiota short-chain fatty acids and their impact on the host thyroid function and diseases.Frontiers in endocrinology · 2023Review
- Profiles of gut microbiota in obese-insulin-resistant rats treated with biotics.European journal of nutrition · 2022Article
- Unlocking the Potential of the Human Microbiome for Identifying Disease Diagnostic Biomarkers.Diagnostics (Basel, Switzerland) · 2022Review
- Individuals with Metabolic Syndrome Show Altered Fecal Lipidomic Profiles with No Signs of Intestinal Inflammation or Increased Intestinal Permeability.Metabolites · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) has become a worldwide health issue. Recent studies reveal that the human gut microbiota exerts a significant role in the pathogenesis of this disease. While drug treatments may greatly improve metabolic symptoms, little is known about the gut microbiota composition of these treated MetS patients. This study aimed to characterize the gut microbiota composition of treated-MetS patients and analyse the possibility of using gut microbiota as an indicator of metabolic conditions. 16S rRNA metagenomic sequencing approach was used to profile gut microbiota of 111 treated MetS patients from The Cohort of patients at a high Risk of Cardiovascular Events (CORE)-Thailand registry. Our results show that the gut microbiota profiles of MetS patients are diverse across individuals, but can be classified based on their similarity into three groups or enterotypes. We also showed several associations between species abundance and metabolic parameters that are enterotype specific. These findings suggest that information on the gut microbiota can be useful for assessing treatment options for MetS patients. In addition, any correlations between species abundance and human properties are likely specific to each microbial community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.